|
Post by porkini on Dec 17, 2020 17:47:22 GMT -5
I'm full of questions: Is there a connection or synergy with this and Qrum Pharma and Dr. Hofmann on board? Note that qrumpharma.com/ now is redirected to mannkindcorp.com/
|
|
|
Post by mango on Dec 17, 2020 17:47:58 GMT -5
Fantastic deal and addition to the bag.
✅ Under the terms of the agreement, MannKind’s sales force will promote Thyquidity to adult endocrinologists, pediatric endocrinologists and other US healthcare providers who treat hypothyroidism. Vertice will make a specified quarterly payment to MannKind to defray the costs of the additional promotional activity and will pay MannKind royalties on gross profit resulting from all sales of Thyquidity.
|
|
|
Post by mnkdfann on Dec 17, 2020 17:50:49 GMT -5
Unless I dreamt it, Mannkind (e.g. Castagna) has talked about doing such co-promotions (at Annual Meetings and the like) through its sales force off and on for over 2 years.
So glad they finally landed a fish.
|
|
|
Post by Clement on Dec 17, 2020 18:01:01 GMT -5
Fantastic deal and addition to the bag. ✅ Under the terms of the agreement, MannKind’s sales force will promote Thyquidity to adult endocrinologists, pediatric endocrinologists and other US healthcare providers who treat hypothyroidism. Vertice will make a specified quarterly payment to MannKind to defray the costs of the additional promotional activity and will pay MannKind royalties on gross profit resulting from all sales of Thyquidity." launch of Thyquidity in 1Q 2021.” So maybe the specified quarterly payment begins 1Q 2021.
|
|
|
Post by gamblerjag on Dec 17, 2020 18:06:33 GMT -5
Simply outstanding. This has been shaping up to be a December to remember. Isn’t that a car commercial ad? :-)
|
|
|
Post by longliner on Dec 17, 2020 18:07:02 GMT -5
Scott Meyers and Noel Greenberger Heads of Vertice both came from Novartis. Quorum's primary drug (now Mannkind's) is owned by Novartis.
|
|
|
Post by winstonsmith on Dec 17, 2020 18:15:52 GMT -5
Good for Mannkind IMO because the sales force approach is ineffective and a money loser. Might as well lose less money.
VDEX/social media/events are the only ways to grow scripts.
|
|
|
Post by hellodolly on Dec 17, 2020 18:34:01 GMT -5
This is really good news. Levo is the number one prescribed drug in the US. While the Rx count has recently declined, per this article ((https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238309/)), it remains an opportunity that Mike is going to exploit. Just another pathway for sales staff to enter the front door. Getting in because you distribute one of the most prescribed drugs in America, is half the battle. I would imagine that MNKD sales staff are going to pickup some new Endo's along with an overlap on those they already visit. Brilliant. What's to stop MNKD from co-promoting more drugs?
|
|
|
Post by mnkdfann on Dec 17, 2020 18:37:11 GMT -5
Simply outstanding. This has been shaping up to be a December to remember. Isn’t that a car commercial ad? :-) The one on SNL last weekend? I just watched that like an hour ago. It was very funny.
|
|
|
Post by castlerockchris on Dec 17, 2020 18:45:43 GMT -5
After-hours jumped on it, for sure! I would like to speak with the person who bought after hours at $4.50 and ask if they need anymore shares at that price! I would happily part with the shares I purchased today at 3.86.
|
|
|
Post by castlerockchris on Dec 17, 2020 18:50:56 GMT -5
I don't see the value in this arrangement between the two companies. a co-promotion like this is done to essentially bring in revenue to cover part of the cost of the 70 sales reps they have currently. It would likely cover the cost of about 1/3 to 1/2 of the salesforce. A sales rep can effectively sell 2-3 products in their bag, so adding a 2nd is a no brainer to improve efficiency. As important as reducing MNKD SG&A expense, it may help us retain reps as they now have another income stream. I don't mind the idea. Cut our overhead, hopefully allow our reps to make more money, allowing MNKD to have a higher retention rate. Obviously, management needs to make sure Afrezza sales do not slip much. I would love (and prefer) MNKD to cut a similar deal with UTHR, but I don't see that as realistic.
|
|
|
Post by mango on Dec 17, 2020 18:53:13 GMT -5
Copying/pasting what regenmedicalprovider on ST posted. Liquid levothyroxine (L-T4) is a far superior formulation and results in better control of TSH and more stable levels of circulating T4 and T3. Levothyroxine is among the most prescribed medications in the United States; it is a lifesaving maintenance drug used to treat hypothyroidism. L-T4 overcomes many malabsorption issues such as gastric bypass, autoimmune disorders or the GI tract, drug interference with other meds such proton‐pump inhibitors. Many diabetics also have thyroid disorders. This is a very good cooperative sales arrangement. Nice article here: www.ncbi.nlm.nih.gov/pmc/articles/PMC6209618/
|
|
|
Post by mango on Dec 17, 2020 18:54:41 GMT -5
This is really good news. Levo is the number one prescribed drug in the US. While the Rx count has recently declined, per this article ((https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238309/)), it remains an opportunity that Mike is going to exploit. Just another pathway for sales staff to enter the front door. Getting in because you distribute one of the most prescribed drugs in America, is half the battle. I would imagine that MNKD sales staff are going to pickup some new Endo's along with an overlap on those they already visit. Brilliant. What's to stop MNKD from co-promoting more drugs? Also gets them in the door of Peds Endos. Overall great deal.
|
|
|
Post by biffn on Dec 17, 2020 18:55:34 GMT -5
It may be that anything that adds runway is viewed as very positive by the market. One more positive and at least one less negative puts more emphasis on the company’s future potential.
|
|
|
Post by mnkdfann on Dec 17, 2020 19:03:30 GMT -5
I'm surprised by this too! I don't see the value in this arrangement between the two companies. At least they're not hawking some other Pharma's brand of insulin.
|
|